NeuroVive To Take Traumatic Brain Injury Drug Into Mid-Stage Studies
Executive Summary
Protecting the function of mitochondria may be key to developing medicines to reduce the nerve damage caused by traumatic brain injuries. NeuroVive Pharmaceutical is moving its cyclosporine candidate into Phase IIb studies.
You may also be interested in...
Mitochondrial Medicine Focus Drives NeuroVive Orphan Ambitions
Erik Kinnman, CEO of NeuroVive Pharmaceutical, spoke to Scrip about the company's work in mitochondrial medicine. The company aims to develop orphan drugs to treat rare genetic conditions and seek partners for its NASH and liver cancer projects.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.